A

Aveo Pharmaceuticals Inc
F:VPA1

Watchlist Manager
Aveo Pharmaceuticals Inc
F:VPA1
Watchlist
Price: 13.77 EUR -0.4%
Market Cap: 478.7m EUR

Relative Value

There is not enough data to reliably calculate the relative value of VPA1.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VPA1 Relative Value
Base Case
Not Available
A
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
5.5
Median 5Y
5.5
Industry
7.3
Forward
4.3
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-17.4
Industry
23.3
Forward
-94.8
vs History
vs Industry
Median 3Y
-22.7
Median 5Y
-21.9
Industry
19.8
vs History
vs Industry
Median 3Y
-23.8
Median 5Y
-22.9
Industry
22.6
vs History
vs Industry
Median 3Y
17.9
Median 5Y
17.2
Industry
2.7
vs History
vs Industry
Median 3Y
4.9
Median 5Y
5
Industry
7.6
Forward
3.9
vs History
vs Industry
Median 3Y
5.6
Median 5Y
5.6
Industry
9.4
vs History
vs Industry
Median 3Y
-19
Median 5Y
-18.6
Industry
4.7
vs History
vs Industry
Median 3Y
-19
Median 5Y
-18.5
Industry
4.8
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-19.7
Industry
5.3
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-19.7
Industry
3.8
vs History
vs Industry
Median 3Y
24.7
Median 5Y
24.7
Industry
5

Multiples Across Competitors

VPA1 Competitors Multiples
Aveo Pharmaceuticals Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aveo Pharmaceuticals Inc
F:VPA1
476.7m EUR 5.9 -19.2 -20.8 -20.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 917 039.3 -161 202.7 -195 751.4 -193 517.7
US
Abbvie Inc
NYSE:ABBV
344.4B USD 6 82.9 15.7 23.2
US
Amgen Inc
NASDAQ:AMGN
161.5B USD 4.7 27.2 14.6 24
US
Gilead Sciences Inc
NASDAQ:GILD
142.6B USD 5 23.9 10.4 14.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.2B USD 11.1 -124.6 26.6 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 077.1 -530 -577.1 -561.7
AU
CSL Ltd
ASX:CSL
116.7B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.6B USD 4.3 13.5 12 13.5
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.4 -66.1 -59.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42B USD 17.9 -155.9 -699.4 -350.5
P/E Multiple
Earnings Growth PEG
US
A
Aveo Pharmaceuticals Inc
F:VPA1
Average P/E: 35.1
Negative Multiple: -19.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 202.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
82.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.9
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Aveo Pharmaceuticals Inc
F:VPA1
Average EV/EBITDA: 16.1
Negative Multiple: -20.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 751.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.6
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -699.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Aveo Pharmaceuticals Inc
F:VPA1
Average EV/EBIT: 20.7
Negative Multiple: -20.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 517.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
24
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.3
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.5 N/A N/A